Litigation Details for UCB, Inc. v. Catalent Pharma Solutions Inc. (E.D. Ky. 2021)
✉ Email this page to a colleague
UCB, Inc. v. Catalent Pharma Solutions Inc. (E.D. Ky. 2021)
| Docket | ⤷ Try a Trial | Date Filed | 2021-02-04 |
| Court | District Court, E.D. Kentucky | Date Terminated | 2021-12-15 |
| Cause | 35:145 Patent Infringement | Assigned To | Gregory F. VanTatenhove |
| Jury Demand | Referred To | ||
| Patents | RE38,551 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in UCB, Inc. v. Catalent Pharma Solutions Inc.
The small molecule drug covered by the patent cited in this case is ⤷ Try a Trial .
Details for UCB, Inc. v. Catalent Pharma Solutions Inc. (E.D. Ky. 2021)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2021-05-12 | 59 | New Drug Applications 1 U.S. Patent No. RE38,551 (the “ ‘551 Patent”). 2 VIMPAT® is an antiepilectic…dispute. On July 6, 2004, the U.S. Patent Office issued a patent to Dr. Harold Kohn, which described …product that is protected by a patent, such as lacosamide, before the patent expires. In 1984, however, … development by allowing “patent holders to extend the term of their patent up to five years for delays…would constitute patent infringement under Section 271(a) of the United States Patent Act, 5 and this | External link to document | |
| 2021-11-28 | 60 | interest in United States Reissued Patent No. RE38,551 (“the ‘551 Patent”), which claims the chemical compound… claim for patent infringement because the product is a patented invention and the patent term has not… sells, or imports a patented invention without authority “infringes the patent.” However, the Hatch-… for patent infringement.” [Id.] They also argue the complaint fails to state a claim for patent infringement…any patented invention, within the United States or imports into the United States any patented | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
